The Supervisory Board of
Schering AG, Germany (FSE: SCH, NYSE: SHR) today announced that it shares the
positive view of the Executive Board of Schering AG regarding the takeover
offer by Bayer AG. The Supervisory Board will also recommend to Schering AG's
shareholders to accept the offer once the formal offer documents have been
published and assessed.
Schering AG is a research-based pharmaceutical company. Its activities
are focused on four business areas: Gynecology&Andrology, Oncology,
Diagnostic Imaging as well as Specialized Therapeutics for disabling
diseases. As a global player with innovative products, Schering AG aims for
leading positions in specialized markets worldwide. With in-house R&D and
supported by an excellent global network of external partners, Schering AG is
securing a promising product pipeline. Using new ideas, Schering AG aims to
make a recognized contribution to medical progress and strives to improve the
quality of life: making medicine work.
This press release has been published by Corporate Communication of
Schering AG, Berlin, Germany.
Find additional information at: schering.de/eng
At an appropriate time, Schering Aktiengesellschaft will file a
solicitation/recommendation statement with the U.S. Securities and Exchange
Commission relating to any tender offer for the ordinary shares or American
Depositary Shares of Schering Aktiengesellschaft. Holders of ordinary shares
and American depositary shares of Schering Aktiengesellschaft are advised to
read such solicitation/recommendation statement when it becomes available
because it will contain important information. Holders of ordinary shares and
American depositary shares of Schering Aktiengesellschaft will be able to
obtain such solicitation/recommendation statement and other filed documents
when they become available free of charge at the U.S. Securities and Exchange
Commission's website (sec) and at Schering
Aktiengesellschaft's website (schering.de/eng).
Certain statements in this press release that are neither reported
financial results nor other historical information are forward-looking
statements, including but not limited to, statements that are predictions of
or indicate future events, trends, plans or objectives. Undue reliance should
not be placed on such statements because, by their nature, they are subject
to known and unknown risks and uncertainties and can be affected by other
factors that could cause actual results and Schering AG's plans and
objectives to differ materially from those expressed or implied in the
forward-looking statements. Certain factors that may cause such differences
are discussed in our Form 20-F and Form 6-K reports filed with the U.S.
Securities and Exchange Commission. Schering AG undertakes no obligation to
update publicly or revise any of these forward-looking statements, whether to
reflect new information or future events or circumstances or otherwise.
SOURCE Schering AG
schering.de/eng